Loading…
Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial
Saved in:
| Published in: | Blood 2017-09, Vol.130 (12), p.1477-1480 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c408t-35b5e9ee0c2d10ca26206563195061d2d9c917cae93fce39401a4e1721db68d23 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c408t-35b5e9ee0c2d10ca26206563195061d2d9c917cae93fce39401a4e1721db68d23 |
| container_end_page | 1480 |
| container_issue | 12 |
| container_start_page | 1477 |
| container_title | Blood |
| container_volume | 130 |
| creator | Krämer, Isabelle Stilgenbauer, Stephan Dietrich, Sascha Böttcher, Sebastian Zeis, Matthias Stadler, Michael Bittenbring, Jörg Uharek, Lutz Scheid, Christof Hegenbart, Ute Ho, Anthony Hallek, Michael Kneba, Michael Schmitz, Norbert Döhner, Hartmut Dreger, Peter |
| description | |
| doi_str_mv | 10.1182/blood-2017-04-775841 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1921134959</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497120328561</els_id><sourcerecordid>1921134959</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-35b5e9ee0c2d10ca26206563195061d2d9c917cae93fce39401a4e1721db68d23</originalsourceid><addsrcrecordid>eNp9kE2LFDEQhoMo7rj6D0Ry9BKtSqc_4kFYBp1dGPCggreQSVfvRDOdNsm47L8346wePRVFPfUW9TD2EuEN4iDf7kKMo5CAvQAl-r4dFD5iK2zlIAAkPGYrAOiE0j1esGc5fwdA1cj2KbuQQ4_d0OGKhasQ4i3N5B3f08GWuERPpXaOQuAl2Tkvwc7FFh9nPsXE9_52L5LPP_h6u33HEcQ92VRHNelOHBceJ172xDd1_HlzgppvNcjb8Jw9mWzI9OKhXrKvHz98WV-L7afNzfpqK5yCoYim3bWkicDJEcFZ2Uno2q5B3UKHoxy109g7S7qZHDVaAVpF2Escd90wyuaSvT7nLin-PFIu5uDz6R87Uzxmg1oiNkq3uqLqjLoUc040mSX5g033BsGcPJs_ns3JswFlzp7r2quHC8fdgcZ_S3_FVuD9GaD65y9PyWTnaXY0-kSumDH6_1_4DfNujYQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1921134959</pqid></control><display><type>article</type><title>Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial</title><source>ScienceDirect®</source><creator>Krämer, Isabelle ; Stilgenbauer, Stephan ; Dietrich, Sascha ; Böttcher, Sebastian ; Zeis, Matthias ; Stadler, Michael ; Bittenbring, Jörg ; Uharek, Lutz ; Scheid, Christof ; Hegenbart, Ute ; Ho, Anthony ; Hallek, Michael ; Kneba, Michael ; Schmitz, Norbert ; Döhner, Hartmut ; Dreger, Peter</creator><creatorcontrib>Krämer, Isabelle ; Stilgenbauer, Stephan ; Dietrich, Sascha ; Böttcher, Sebastian ; Zeis, Matthias ; Stadler, Michael ; Bittenbring, Jörg ; Uharek, Lutz ; Scheid, Christof ; Hegenbart, Ute ; Ho, Anthony ; Hallek, Michael ; Kneba, Michael ; Schmitz, Norbert ; Döhner, Hartmut ; Dreger, Peter</creatorcontrib><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2017-04-775841</identifier><identifier>PMID: 28716861</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Aged ; Alemtuzumab - therapeutic use ; Allografts ; Antineoplastic Agents, Immunological - therapeutic use ; Combined Modality Therapy ; Disease-Free Survival ; Female ; Follow-Up Studies ; Graft vs Host Disease - epidemiology ; Graft vs Host Disease - etiology ; Humans ; Kaplan-Meier Estimate ; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy ; Leukemia, Lymphocytic, Chronic, B-Cell - mortality ; Leukemia, Lymphocytic, Chronic, B-Cell - pathology ; Leukemia, Lymphocytic, Chronic, B-Cell - therapy ; Male ; Middle Aged ; Molecular Targeted Therapy ; Neoplasm, Residual ; Peripheral Blood Stem Cell Transplantation - statistics & numerical data ; Prognosis ; Pyrazoles - therapeutic use ; Pyrimidines - therapeutic use ; Salvage Therapy ; Treatment Outcome</subject><ispartof>Blood, 2017-09, Vol.130 (12), p.1477-1480</ispartof><rights>2017 American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-35b5e9ee0c2d10ca26206563195061d2d9c917cae93fce39401a4e1721db68d23</citedby><cites>FETCH-LOGICAL-c408t-35b5e9ee0c2d10ca26206563195061d2d9c917cae93fce39401a4e1721db68d23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0006497120328561$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>315,786,790,3568,27957,27958,45815</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28716861$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Krämer, Isabelle</creatorcontrib><creatorcontrib>Stilgenbauer, Stephan</creatorcontrib><creatorcontrib>Dietrich, Sascha</creatorcontrib><creatorcontrib>Böttcher, Sebastian</creatorcontrib><creatorcontrib>Zeis, Matthias</creatorcontrib><creatorcontrib>Stadler, Michael</creatorcontrib><creatorcontrib>Bittenbring, Jörg</creatorcontrib><creatorcontrib>Uharek, Lutz</creatorcontrib><creatorcontrib>Scheid, Christof</creatorcontrib><creatorcontrib>Hegenbart, Ute</creatorcontrib><creatorcontrib>Ho, Anthony</creatorcontrib><creatorcontrib>Hallek, Michael</creatorcontrib><creatorcontrib>Kneba, Michael</creatorcontrib><creatorcontrib>Schmitz, Norbert</creatorcontrib><creatorcontrib>Döhner, Hartmut</creatorcontrib><creatorcontrib>Dreger, Peter</creatorcontrib><title>Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial</title><title>Blood</title><addtitle>Blood</addtitle><subject>Adult</subject><subject>Aged</subject><subject>Alemtuzumab - therapeutic use</subject><subject>Allografts</subject><subject>Antineoplastic Agents, Immunological - therapeutic use</subject><subject>Combined Modality Therapy</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Graft vs Host Disease - epidemiology</subject><subject>Graft vs Host Disease - etiology</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - mortality</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - pathology</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Molecular Targeted Therapy</subject><subject>Neoplasm, Residual</subject><subject>Peripheral Blood Stem Cell Transplantation - statistics & numerical data</subject><subject>Prognosis</subject><subject>Pyrazoles - therapeutic use</subject><subject>Pyrimidines - therapeutic use</subject><subject>Salvage Therapy</subject><subject>Treatment Outcome</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9kE2LFDEQhoMo7rj6D0Ry9BKtSqc_4kFYBp1dGPCggreQSVfvRDOdNsm47L8346wePRVFPfUW9TD2EuEN4iDf7kKMo5CAvQAl-r4dFD5iK2zlIAAkPGYrAOiE0j1esGc5fwdA1cj2KbuQQ4_d0OGKhasQ4i3N5B3f08GWuERPpXaOQuAl2Tkvwc7FFh9nPsXE9_52L5LPP_h6u33HEcQ92VRHNelOHBceJ172xDd1_HlzgppvNcjb8Jw9mWzI9OKhXrKvHz98WV-L7afNzfpqK5yCoYim3bWkicDJEcFZ2Uno2q5B3UKHoxy109g7S7qZHDVaAVpF2Escd90wyuaSvT7nLin-PFIu5uDz6R87Uzxmg1oiNkq3uqLqjLoUc040mSX5g033BsGcPJs_ns3JswFlzp7r2quHC8fdgcZ_S3_FVuD9GaD65y9PyWTnaXY0-kSumDH6_1_4DfNujYQ</recordid><startdate>20170921</startdate><enddate>20170921</enddate><creator>Krämer, Isabelle</creator><creator>Stilgenbauer, Stephan</creator><creator>Dietrich, Sascha</creator><creator>Böttcher, Sebastian</creator><creator>Zeis, Matthias</creator><creator>Stadler, Michael</creator><creator>Bittenbring, Jörg</creator><creator>Uharek, Lutz</creator><creator>Scheid, Christof</creator><creator>Hegenbart, Ute</creator><creator>Ho, Anthony</creator><creator>Hallek, Michael</creator><creator>Kneba, Michael</creator><creator>Schmitz, Norbert</creator><creator>Döhner, Hartmut</creator><creator>Dreger, Peter</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170921</creationdate><title>Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial</title><author>Krämer, Isabelle ; Stilgenbauer, Stephan ; Dietrich, Sascha ; Böttcher, Sebastian ; Zeis, Matthias ; Stadler, Michael ; Bittenbring, Jörg ; Uharek, Lutz ; Scheid, Christof ; Hegenbart, Ute ; Ho, Anthony ; Hallek, Michael ; Kneba, Michael ; Schmitz, Norbert ; Döhner, Hartmut ; Dreger, Peter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-35b5e9ee0c2d10ca26206563195061d2d9c917cae93fce39401a4e1721db68d23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Alemtuzumab - therapeutic use</topic><topic>Allografts</topic><topic>Antineoplastic Agents, Immunological - therapeutic use</topic><topic>Combined Modality Therapy</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Graft vs Host Disease - epidemiology</topic><topic>Graft vs Host Disease - etiology</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - mortality</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - pathology</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Molecular Targeted Therapy</topic><topic>Neoplasm, Residual</topic><topic>Peripheral Blood Stem Cell Transplantation - statistics & numerical data</topic><topic>Prognosis</topic><topic>Pyrazoles - therapeutic use</topic><topic>Pyrimidines - therapeutic use</topic><topic>Salvage Therapy</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Krämer, Isabelle</creatorcontrib><creatorcontrib>Stilgenbauer, Stephan</creatorcontrib><creatorcontrib>Dietrich, Sascha</creatorcontrib><creatorcontrib>Böttcher, Sebastian</creatorcontrib><creatorcontrib>Zeis, Matthias</creatorcontrib><creatorcontrib>Stadler, Michael</creatorcontrib><creatorcontrib>Bittenbring, Jörg</creatorcontrib><creatorcontrib>Uharek, Lutz</creatorcontrib><creatorcontrib>Scheid, Christof</creatorcontrib><creatorcontrib>Hegenbart, Ute</creatorcontrib><creatorcontrib>Ho, Anthony</creatorcontrib><creatorcontrib>Hallek, Michael</creatorcontrib><creatorcontrib>Kneba, Michael</creatorcontrib><creatorcontrib>Schmitz, Norbert</creatorcontrib><creatorcontrib>Döhner, Hartmut</creatorcontrib><creatorcontrib>Dreger, Peter</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Krämer, Isabelle</au><au>Stilgenbauer, Stephan</au><au>Dietrich, Sascha</au><au>Böttcher, Sebastian</au><au>Zeis, Matthias</au><au>Stadler, Michael</au><au>Bittenbring, Jörg</au><au>Uharek, Lutz</au><au>Scheid, Christof</au><au>Hegenbart, Ute</au><au>Ho, Anthony</au><au>Hallek, Michael</au><au>Kneba, Michael</au><au>Schmitz, Norbert</au><au>Döhner, Hartmut</au><au>Dreger, Peter</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>2017-09-21</date><risdate>2017</risdate><volume>130</volume><issue>12</issue><spage>1477</spage><epage>1480</epage><pages>1477-1480</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><notes>SourceType-Other Sources-1</notes><notes>ObjectType-Article-2</notes><notes>content type line 63</notes><notes>ObjectType-Feature-1</notes><notes>ObjectType-Correspondence-3</notes><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28716861</pmid><doi>10.1182/blood-2017-04-775841</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-4971 |
| ispartof | Blood, 2017-09, Vol.130 (12), p.1477-1480 |
| issn | 0006-4971 1528-0020 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1921134959 |
| source | ScienceDirect® |
| subjects | Adult Aged Alemtuzumab - therapeutic use Allografts Antineoplastic Agents, Immunological - therapeutic use Combined Modality Therapy Disease-Free Survival Female Follow-Up Studies Graft vs Host Disease - epidemiology Graft vs Host Disease - etiology Humans Kaplan-Meier Estimate Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - mortality Leukemia, Lymphocytic, Chronic, B-Cell - pathology Leukemia, Lymphocytic, Chronic, B-Cell - therapy Male Middle Aged Molecular Targeted Therapy Neoplasm, Residual Peripheral Blood Stem Cell Transplantation - statistics & numerical data Prognosis Pyrazoles - therapeutic use Pyrimidines - therapeutic use Salvage Therapy Treatment Outcome |
| title | Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T07%3A50%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Allogeneic%20hematopoietic%20cell%20transplantation%20for%20high-risk%20CLL:%2010-year%20follow-up%20of%20the%20GCLLSG%20CLL3X%20trial&rft.jtitle=Blood&rft.au=Kr%C3%A4mer,%20Isabelle&rft.date=2017-09-21&rft.volume=130&rft.issue=12&rft.spage=1477&rft.epage=1480&rft.pages=1477-1480&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2017-04-775841&rft_dat=%3Cproquest_cross%3E1921134959%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c408t-35b5e9ee0c2d10ca26206563195061d2d9c917cae93fce39401a4e1721db68d23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1921134959&rft_id=info:pmid/28716861&rfr_iscdi=true |